Comparison of OS, LFS, NRM, and CIR for AML recipients between recipients of autotransplant followed by pembrolizumab vs propensity score–matched recipients of allotransplant: OS (A), LFS (B), CIR (C), NRM (D), and postrelapse survival (E).